Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Enochian BioSciences, Inc.

Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
From Enochian BioSciences, Inc.
Via GlobeNewswire
Tickers ENOB
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
From Enochian BioSciences, Inc.
Via GlobeNewswire
Tickers ENOB
Enochian BioSciences’ CEO Letter to Shareholders
From Enochian BioSciences, Inc.
Via GlobeNewswire
Tickers ENOB
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher
From Enochian BioSciences, Inc.
Via GlobeNewswire
Tickers ENOB
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
From Enochian BioSciences, Inc.
Via GlobeNewswire
Tickers ENOB
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022
From Enochian BioSciences, Inc.
Via GlobeNewswire
Tickers ENOB
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022
From Enochian BioSciences, Inc.
Via GlobeNewswire
Tickers ENOB
Enochian BioSciences Forges Ahead With Focused Approach, Promising Future
From Enochian BioSciences, Inc.
Via GlobeNewswire
Tickers ENOB
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-K
From Enochian BioSciences, Inc.
Via GlobeNewswire
Tickers ENOB
Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform
From Enochian BioSciences, Inc.
Via GlobeNewswire
Tickers ENOB
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.